Harnessing immune responses in the tumor microenvironment: All signals needed

Research output: Contribution to journalArticlepeer-review

Abstract

An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.

Original languageEnglish (US)
Pages (from-to)6061-6063
Number of pages3
JournalClinical Cancer Research
Volume19
Issue number22
DOIs
StatePublished - Nov 15 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Harnessing immune responses in the tumor microenvironment: All signals needed'. Together they form a unique fingerprint.

Cite this